AsymBio

AsymBio, a strategic business unit of Asymchem Group, operates as a specialized biopharmaceutical Contract Development and Manufacturing Organization (CDMO). The company focuses on providing comprehensive services for novel conjugated drugs, antibodies, and recombinant protein drugs, leveraging advanced technology platforms and extensive project experience. AsymBio is dedicated to supporting global biopharmaceutical clients through every stage of drug development, from early-stage research and process development to commercial-scale manufacturing. Their mission is to act as a reliable partner, facilitating innovation and accelerating the commercialization of life-saving therapies. The company's expertise spans critical areas such as developability assessment, analytical science, rigorous quality control, and navigating complex regulatory affairs, ensuring a seamless transition from concept to market. AsymBio's operational capabilities are driven by a skilled workforce, and you can Meet AsymBio's team to understand the expertise behind their comprehensive service offerings. The company reported revenue of $28.0M and operates with 500 - 1,000 employees across its single location. AsymBio's commitment to excellence and its integrated service model position it as a key player in the biopharmaceutical manufacturing sector, aiming to empower clients with efficient and high-quality solutions for their most challenging drug development projects.